Your session is about to expire
← Back to Search
Repetitive Transcranial Magnetic Stimulation (rTMS) for Depression (rTMS Trial)
rTMS Trial Summary
This trial is testing a new brain stimulation treatment to help veterans with multiple mental disorders. The treatment is designed to improve problem solving and adaptive cognition.
- Depression
- Mental Health
- Repetitive Transcranial Magnetic Stimulation
- Psychosocial Disability
- Post-Traumatic Stress Disorder
- Anxiety
rTMS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.rTMS Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You have a moderate or severe brain injury based on guidelines used by the VA/DoD.You have or had schizophrenia, bipolar disorder, or certain types of dementia.You have a medical condition that is not stable or under control, such as heart, kidney, stomach, lung, or hormonal problems.You have a brain or spinal cord disease that is getting worse over time.You are currently taking part in or planning to join another therapy study.You have a history of seizures or a condition that causes seizures.
- Group 1: Dose 10
- Group 2: Dose 7
- Group 3: Dose 2
- Group 4: Dose 6
- Group 5: Dose 8
- Group 6: Dose 1
- Group 7: Dose 9
- Group 8: Dose 5
- Group 9: Dose 3
- Group 10: Dose 4
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are accepted for this medical research initiative?
"Affirmative. Clinicaltrials.gov indicates that this clinical exploration, which was initially advertised on February 1st 2019, is actively looking for volunteers. There is a need to enlist 50 patients from one particular site."
What is the criteria for enrollment in this trial?
"This trial is searching for 50 people aged 18-60 who suffer from depression. To be eligible, applicants must meet this criteria."
Is enrollment for this trial still open to the public?
"Per the clinicaltrials.gov website, this research is still in progress and actively seeking participants. The initial posting date was February 1st 2019 with a most recent update occurring on September 15th 2022."
Is Repetitive Transcranial Magnetic Stimulation (rTMS) sanctioned by the FDA?
"Our team at Power rated the safety of Repetitive Transcranial magnetic stimulation (rTMS) as a 1 since this is a Phase 1 trial. Thus, there are only preliminary findings that suggest its efficacy and protection from hazards."
Is the age threshold for this research limited to 30 years or above?
"The eligibility criteria for this medical trial requires that potential participants are aged between 18 and 60 years. Those younger than 18 have access to 261 trials, while those older than 65 can choose from 1,226 other studies."
What is the primary objective of this research endeavor?
"This trial's primary endpoint is to accurately assess patients' psychosocial functioning over a 4-week period. Secondary endpoints include the Mood and Anxiety Symptom Questionnaire (MASQ), which uses a five point Likert scale ranging from "not at all" to "extremely", the Inventory of Depression and Anxious Symptoms (IDAS-II) with responses scored between 1 and 5, and the Hamilton Scale for Depression (HAM-D). This latter assessment entails eight items rated on a 0 - 4 scale while nine are ranked from 0 - 2. Results can range in severity from mild to severe."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger